![Date for Immunicum’s](/news-release/logo/240414/0/240414.jpg?lastModified=12%2F09%2F2016%2022%3A55%3A20&size=2)
Date for Immunicum’s interim report for the period July 2013 – March 2014 changed
April 15, 2014 04:33 ET
|
Immunicum AB
Göteborg, Sweden, 2014-04-15 10:33 CEST (GLOBE NEWSWIRE) --
Immunicum AB (publ) (”Immunicum”) has decided to change the date of publication of its interim report for the period 1 July 2013 – 31...
![Immunicum has comple](/news-release/logo/240414/0/240414.jpg?lastModified=12%2F09%2F2016%2022%3A55%3A20&size=2)
Immunicum has completed a private placement and resolved on a fully underwritten rights issue
April 02, 2014 02:50 ET
|
Immunicum AB
Göteborg, Sweden, 2014-04-02 08:50 CEST (GLOBE NEWSWIRE) --
Not for distribution, directly or indirectly, in or into the United States, Australia, Canada, Singapore, Switzerland, South Africa,...
![Immunicum har genomf](/news-release/logo/240414/0/240414.jpg?lastModified=12%2F09%2F2016%2022%3A55%3A20&size=2)
Immunicum har genomfört en riktad nyemission och beslutat om en fullt garanterad företrädesemission
April 02, 2014 02:50 ET
|
Immunicum AB
Göteborg, 2014-04-02 08:50 CEST (GLOBE NEWSWIRE) --
Ej för distribution, direkt eller indirekt, inom eller till USA, Australien, Kanada, Singapore, Schweiz, Sydafrika, Japan, Hongkong, eller Nya...
![Immunicum slutrappor](/news-release/logo/240414/0/240414.jpg?lastModified=12%2F09%2F2016%2022%3A55%3A20&size=2)
Immunicum slutrapporterar positiva fas I/II säkerhetsdata samt lovande överlevnadsdata vid behandling av metastaserande njurcancer
March 31, 2014 02:56 ET
|
Immunicum AB
Göteborg, 2014-03-31 08:56 CEST (GLOBE NEWSWIRE) --
Immunicum® AB (publ) har idag lämnat in en slutrapport till Läkemedelsverket avseende sin kliniska fas I/II-studie på 12 patienter med...
![Immunicum submits th](/news-release/logo/240414/0/240414.jpg?lastModified=12%2F09%2F2016%2022%3A55%3A20&size=2)
Immunicum submits the final report for its phase I/II trial in metastatic renal cell carcinoma showing positive safety data and promising survival data
March 31, 2014 02:56 ET
|
Immunicum AB
Göteborg, Sweden, 2014-03-31 08:56 CEST (GLOBE NEWSWIRE) --
Immunicum® AB (publ) today submitted the final report to the Swedish Medical Products Agency regarding its clinical phase I/II study in 12...
![Immunicum meddelar a](/news-release/logo/240414/0/240414.jpg?lastModified=12%2F09%2F2016%2022%3A55%3A20&size=2)
Immunicum meddelar att ett abstract med resultat från en njurcancerstudie har godkänts för presentation på det årliga ASCO-mötet i Chicago
March 27, 2014 05:25 ET
|
Immunicum AB
Göteborg, 2014-03-27 10:25 CET (GLOBE NEWSWIRE) --
Immunicum meddelar att ett abstract har godkänts för presentation vid American Society of Clinical Oncologys, ASCOs, årliga konvent som hålls i...
![Immunicum’s abstract](/news-release/logo/240414/0/240414.jpg?lastModified=12%2F09%2F2016%2022%3A55%3A20&size=2)
Immunicum’s abstract with data from a kidney cancer study has been approved for presentation at the 2014 ASCO Annual Meeting in Chicago
March 27, 2014 05:25 ET
|
Immunicum AB
Göteborg, Sweden, 2014-03-27 10:25 CET (GLOBE NEWSWIRE) --
Immunicum today announced that an abstract has been approved to for presentation at the American Society of Clinical Oncology’s’s, ASCO,...
![Immunicum reports pr](/news-release/logo/240414/0/240414.jpg?lastModified=12%2F09%2F2016%2022%3A55%3A20&size=2)
Immunicum reports promising preclinical results for its CD70 technology in adoptive immunotherapy
March 06, 2014 02:40 ET
|
Immunicum AB
Gothenburg, Sweden, 2014-03-06 08:40 CET (GLOBE NEWSWIRE) --
Promising data for Immunicum’s CD70-technology for adoptive immunotherapy are today being published in a scientific journal. The results...
![Immunicum rapportera](/news-release/logo/240414/0/240414.jpg?lastModified=12%2F09%2F2016%2022%3A55%3A20&size=2)
Immunicum rapporterar lovande prekliniska resultat för sin CD70-teknologi inom adoptiv immunterapi
March 06, 2014 02:40 ET
|
Immunicum AB
Göteborg, 2014-03-06 08:40 CET (GLOBE NEWSWIRE) --
Idag publiceras lovande data för Immunicums CD70-teknologi för adoptiv immunterapi. Resultaten indikerar en robust metod att expandera...
![Immunicum: Interim R](/news-release/logo/240414/0/240414.jpg?lastModified=12%2F09%2F2016%2022%3A55%3A20&size=2)
Immunicum: Interim Report July - December 2013
February 18, 2014 02:59 ET
|
Immunicum AB
Gothenburg, Sweden, 2014-02-18 08:59 CET (GLOBE NEWSWIRE) --
Second half of 2013 compared with the same period in 2012
Profit/Loss
The net loss for the period July 1 - December 31, 2013...